Sanofi Extends Cancer Ambitions With IL-2 Drug And Keytruda Combination

Seeking Cancer Blockbuster To Match Dupixent Success

 
• By Andrew McConaghie

Sanofi is playing catch-up in oncology and hopes Synthorx’s expertise will help the group advance.

Sanofi_Berlin
Dupixent is helping to power the new Sanofi, but the company wants to become a major player in oncology as well.

More from Business

More from Scrip